0

    538965

    CONCORD

    img img img img
    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    Concord Drugs Limited Share Price Today

    Investment Returns

    Over 1 Month -6.12% Over 3 Months 7.92% Over 6 Months -8.39% Over 1 Year 45.33%
    demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    Concord Drugs Limited fundamentals


    • Market cap (Cr) [-]
    • P/E Ratio (TTM) [-]
    • Beta [-]
    • Book Value / share [-]
    • Return on equity [-]%
    • EPS (TTM) [-]
    • Dividend yield [-]%
    • Net profit/quarter (Cr) [-]
    info icon alternate text
    • Market cap (Cr) 99.30
    • P/E Ratio (TTM) 98.04
    • Beta 0.33
    • Book Value / share 36.82
    • Return on equity 0.88%
    • EPS (TTM) 0.79
    • Dividend yield [-]%
    • Net profit/quarter (Cr) 0.52
    info icon alternate text

    Concord Drugs Limited Financials

    • Key Results
    • Key Ratios
    • Balance sheet
    • Cash Flow
    • Competition
    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 35.55
    Operating Expense 34.82
    Net Profit 0.52
    Net Profit Margin (%) 1.46
    Earnings Per Share (EPS) 0.46
    EBITDA 1.42
    Effective Tax Rate (%) 30.13
    Particulars DEC 2025 (Values in Cr)
    Revenue 16.84
    Operating Expense 16.57
    Net Profit 0.22
    Net Profit Margin (%) 1.30
    Earnings Per Share (EPS) 0.16
    EBITDA 0.88
    Effective Tax Rate (%) 27.58
    Particulars SEP 2025 (Values in Cr)
    Revenue 10.07
    Operating Expense 9.81
    Net Profit 0.19
    Net Profit Margin (%) 1.88
    Earnings Per Share (EPS) 0.19
    EBITDA 1.01
    Effective Tax Rate (%) 29.62
    Particulars JUN 2025 (Values in Cr)
    Revenue 13.38
    Operating Expense 13.23
    Net Profit 0.11
    Net Profit Margin (%) 0.82
    Earnings Per Share (EPS) 0.11
    EBITDA 0.94
    Effective Tax Rate (%) 26.66
    Particulars MAR 2025 (Values in Cr)
    Revenue 7.96
    Operating Expense 7.94
    Net Profit 0.01
    Net Profit Margin (%) 0.12
    Earnings Per Share (EPS) 0.01
    EBITDA 0.92
    Effective Tax Rate (%) 50.00
    Particulars MAR 2026 (Values in Cr)
    Revenue 75.85
    Operating Expense 74.44
    Net Profit 1.04
    Net Profit Margin (%) 1.37
    Earnings Per Share (EPS) 0.93
    EBITDA 4.27
    Effective Tax Rate (%) 28.27
    Particulars MAR 2025 (Values in Cr)
    Revenue 36.93
    Operating Expense 36.31
    Net Profit 0.30
    Net Profit Margin (%) 0.81
    Earnings Per Share (EPS) 0.30
    EBITDA 3.78
    Effective Tax Rate (%) 54.68
    Particulars MAR 2024 (Values in Cr)
    Revenue 43.26
    Operating Expense 42.71
    Net Profit 0.42
    Net Profit Margin (%) 0.97
    Earnings Per Share (EPS) 0.42
    EBITDA 3.69
    Effective Tax Rate (%) 25.00
    Particulars MAR 2023 (Values in Cr)
    Revenue 51.31
    Operating Expense 50.19
    Net Profit 0.89
    Net Profit Margin (%) 1.73
    Earnings Per Share (EPS) 0.96
    EBITDA 4.35
    Effective Tax Rate (%) 20.35
    Particulars MAR 2022 (Values in Cr)
    Revenue 58.96
    Operating Expense 56.81
    Net Profit 1.59
    Net Profit Margin (%) 2.69
    Earnings Per Share (EPS) 1.82
    EBITDA 5.68
    Effective Tax Rate (%) 28.88
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 34.11
    ROE % 1.00
    ROCE % 4.94
    Total Debt to Total Equity 0.54
    EBITDA Margin 9.17
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 33.82
    ROE % 1.43
    ROCE % 4.75
    Total Debt to Total Equity 0.53
    EBITDA Margin 9.02
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 33.43
    ROE % 3.30
    ROCE % 6.04
    Total Debt to Total Equity 0.56
    EBITDA Margin 8.79
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 32.44
    ROE % 5.61
    ROCE % 8.36
    Total Debt to Total Equity 0.58
    EBITDA Margin 9.65
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 34.11
    ROE % 0.88
    ROCE % 4.49
    Total Debt to Total Equity 0.47
    EBITDA Margin 10.24
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 33.82
    ROE % 1.28
    ROCE % 4.24
    Total Debt to Total Equity 0.47
    EBITDA Margin 8.53
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 33.43
    ROE % 2.96
    ROCE % 5.67
    Total Debt to Total Equity 0.53
    EBITDA Margin 8.48
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 32.44
    ROE % 5.77
    ROCE % 8.80
    Total Debt to Total Equity 0.53
    EBITDA Margin 9.65
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 30.61
    ROE % 1.59
    ROCE % 5.01
    Total Debt to Total Equity 0.45
    EBITDA Margin 6.46
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 0.22
    Total Assets 65.14
    Total Liabilities 65.14
    Total Equity 34.11
    Share Outstanding 1
    Price to Book Ratio 0.91
    Return on Assets (%) 0.51
    Return on Capital (%) 0.66
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 0.17
    Total Assets 58.80
    Total Liabilities 58.80
    Total Equity 33.81
    Share Outstanding 1
    Price to Book Ratio 1.04
    Return on Assets (%) 0.80
    Return on Capital (%) 0.94
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 0.09
    Total Assets 58.23
    Total Liabilities 58.23
    Total Equity 31.70
    Share Outstanding 0
    Price to Book Ratio 0.82
    Return on Assets (%) 1.69
    Return on Capital (%) 2.06
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 0.06
    Total Assets 56.44
    Total Liabilities 56.44
    Total Equity 28.36
    Share Outstanding 0
    Price to Book Ratio 0.89
    Return on Assets (%) 2.82
    Return on Capital (%) 3.62
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 0.21
    Total Assets 58.58
    Total Liabilities 58.58
    Total Equity 34.11
    Share Outstanding 1
    Price to Book Ratio 0.91
    Return on Assets (%) 0.50
    Return on Capital (%) 0.6
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 0.16
    Total Assets 56.29
    Total Liabilities 56.29
    Total Equity 33.81
    Share Outstanding 1
    Price to Book Ratio 1.04
    Return on Assets (%) 0.74
    Return on Capital (%) 0.88
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 0.09
    Total Assets 56.63
    Total Liabilities 56.63
    Total Equity 31.70
    Share Outstanding 0
    Price to Book Ratio 0.82
    Return on Assets (%) 1.57
    Return on Capital (%) 1.92
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 0.06
    Total Assets 56.44
    Total Liabilities 56.44
    Total Equity 28.36
    Share Outstanding 0
    Price to Book Ratio 0.89
    Return on Assets (%) 2.82
    Return on Capital (%) 3.62
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 0.05
    Total Assets 49.88
    Total Liabilities 49.88
    Total Equity 26.76
    Share Outstanding 0
    Price to Book Ratio 0.95
    Return on Assets (%) 6.57
    Return on Capital (%) 8.26
    Particulars MAR 2025 (Values in Cr)
    Net Income 0.69
    Cash from Operations 3.92
    Cash from Investing -2.31
    Cash from Financing -1.42
    Net change in Cash -0.02
    Free Cash Flow 6.25
    Particulars MAR 2024 (Values in Cr)
    Net Income 0.62
    Cash from Operations 1.01
    Cash from Investing -1.00
    Cash from Financing 0.28
    Net change in Cash 0.06
    Free Cash Flow 2.03
    Particulars MAR 2023 (Values in Cr)
    Net Income 1.24
    Cash from Operations 2.04
    Cash from Investing -2.26
    Cash from Financing 0.62
    Net change in Cash 0.02
    Free Cash Flow 2.89
    Particulars MAR 2022 (Values in Cr)
    Net Income 2.24
    Cash from Operations 1.44
    Cash from Investing -2.44
    Cash from Financing 1.67
    Net change in Cash 0.00
    Free Cash Flow 3.90
    Particulars MAR 2025 (Values in Cr)
    Net Income 0.64
    Cash from Operations 3.35
    Cash from Investing -2.31
    Cash from Financing -0.86
    Net change in Cash -0.02
    Free Cash Flow 5.68
    Particulars MAR 2024 (Values in Cr)
    Net Income 0.55
    Cash from Operations 2.16
    Cash from Investing -1.20
    Cash from Financing -0.68
    Net change in Cash 0.06
    Free Cash Flow 3.18
    Particulars MAR 2023 (Values in Cr)
    Net Income 1.12
    Cash from Operations 2.59
    Cash from Investing -2.26
    Cash from Financing 0.05
    Net change in Cash 0.03
    Free Cash Flow 3.44
    Particulars MAR 2022 (Values in Cr)
    Net Income 2.24
    Cash from Operations 1.44
    Cash from Investing -2.44
    Cash from Financing 1.67
    Net change in Cash 0.00
    Free Cash Flow 3.90
    Particulars MAR 2021 (Values in Cr)
    Net Income 4.29
    Cash from Operations 2.08
    Cash from Investing -3.66
    Cash from Financing 2.07
    Net change in Cash 0.02
    Free Cash Flow 5.76
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 32.72 13.52 1.58 250.74 23.12 38.85
    BLISS GVS PHARMA LTD 506.15 40.69 4.49 5368.04 118.35 552.90
    CIPLA LTD 1458.45 30.95 3.42 117820.20 1165.55 1672.20
    FERMENTA BIOTECH LTD. 345.85 15.26 2.50 1017.87 256.40 399.00
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 32.72 22.88 4.21 250.74 23.12 38.85
    AMRUTANJAN HEALTH CARE LTD. 536.85 24.06 4.19 1552.07 490.00 789.95
    ASTRAZENECA PHARMA IND LT 8297.90 108.37 23.76 20744.75 7630.00 9850.00
    BLISS GVS PHARMA LTD 506.15 54.72 4.64 5368.04 118.35 552.90

    Concord Drugs Limited shareholding pattern

    Holding
    45.6%
    54.39%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    News

    Left Arrow
    Right Arrow

    Concord Drugs Limited Technicals Summary

    • EMA & SMA
    • Resistance and Support
    • Delivery and Volume
    • Beta
    • Price Change Analysis
    75.40 -2.64 redarrow
    red-green-graph indicator
    15 Bearish
    1 Bullish
    • 5 Days 76.50
    • 26 Days 78.00
    • 10 Days 76.70
    • 50 Days 78.80
    • 12 Days 76.90
    • 100 Days 78.20
    • 20 Days 77.60
    • 200 Days 73.60
    77.19 PIVOT
    First Support 76.89 First Resistance 77.76 Second Support 76.32 Second Resistance 78.06 Third Support 76.02 Third Resistance 78.63
    RSI 48.03 ADX 16.10 MACD -1.13 Williams % R -48.43 Commodity Channel Index (CCI) -38.53
    Date 2026-07-03 Week 2511.00 Same Day 2692.00 Month 3893.00
    1 Year 0.34 3 Year 0.60
    Over 1 Month
    -6.12% down
    Over 1 Year
    45.33% down
    Over 3 Months
    7.92% down
    Over 3 Years
    42.08% down
    Over 6 Months
    -8.39% down
    Over 5 Years
    19.48% down

    Concord Drugs Limited Corporate Actions

    Top Gainers

    Top Losers

    stock
    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Concord Drugs Ltd?

    Answer Field

    Concord Drugs Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 75.40 as on Jul 06 2026 03:25 PM.

    What is the Market Cap of Concord Drugs Ltd Share?

    Answer Field

    The market cap of Concord Drugs Ltd for NSE ₹ 0.00 & for BSE ₹ 99.30 as on Jul 06 2026 03:25 PM.

    What is the 52 Week High and Low of Concord Drugs Ltd?

    Answer Field

    The 52 Week High and Low of Concord Drugs Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 92.52 and ₹ 49.00.

    What is 1 year return for Concord Drugs Ltd?

    Answer Field

    The 1 year returns on the stock has been 45.33%.

    What is the P/E Ratio of Concord Drugs Ltd Share?

    Answer Field

    As on Jul 06 2026 03:25 PM the price-to-earnings (PE) ratio for Concord Drugs Ltd share is 98.04.

    What is the PB ratio of Concord Drugs Ltd Share?

    Answer Field

    As on Jul 06 2026 03:25 PM, the price-to-book (PB) ratio for Concord Drugs Ltd share is 36.82.

    How to Buy Concord Drugs Ltd Share?

    Answer Field

    You can trade in Concord Drugs Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Concord Drugs Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Concord Drugs Ltd shares on the Bajaj Broking app, follow these steps:

    • Login to the Bajaj Broking App

    • Click on the Search Icon

    • Search “Concord Drugs Ltd”

    • Click on the BUY icon

    • Place a buy order specifying the desired quantity of shares.

    • Click BUY again to complete the purchase

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |